Peter Sander

University of Zurich — Switzerland

Medicine · Health Sciences

53h-index9.1kcitations291works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(83), Mycobacterium research and diagnosis(77), Antibiotic Resistance in Bacteria(33), Gastroesophageal reflux and treatments(19), Reliability and Maintenance Optimization(18)

Publications291 total

Dichalcogenide Fidaxomicin Derivatives to Probe Thiol-Mediated Uptake into Bacteria
ACS Infectious Diseases·2026
Simulated use of the water circuit disinfection device on a Mycobacterium chimaera–contaminated LivaNova 3T Heater Cooler Device: results of mycobacterial and bacterial surveillance
Journal of Hospital Infection·2025Open Access
Revisiting tuberculosis diagnostics: progress, pitfalls, and future directions
Clinical Microbiology and Infection·2025· 1 cited
Dichalcogenide Fidaxomicin Derivatives to Probe Thiol-Mediated Uptake into Bacteria
2025
Prodrug florfenicol amine is activated by intrinsic resistance to target Mycobacterium abscessus
Nature Microbiology·2025Open Access
c-Myc Inhibits Macrophage Antimycobacterial Response in <i>Mycobacterium tuberculosis</i> Infection
The Journal of Infectious Diseases·2025· 2 citedOpen Access
AveloMask, a novel breath aerosol collection kit for airborne <i>Mycobacterium tuberculosis</i> : a proof-of-principle assessment
Journal of Clinical Microbiology·2025Open Access
Selective inhibition of <i>Mycobacterium tuberculosis</i> GpsI unveils a novel strategy to target the RNA metabolism
Nucleic Acids Research·2025Open Access
Dichalcogenide Fidaxomicin Derivatives to Probe Thiol-Mediated Uptake into Bacteria
2025· 1 citedOpen Access
AveloMask, a novel breath aerosol collection kit for airborne <i>Mycobacterium tuberculosis</i> : a proof-of-principle assessment
2025· 1 citedOpen Access
c-Myc inhibits macrophage antimycobacterial response in <i>Mycobacterium tuberculosis</i> infection
2025· 2 citedOpen Access
Switching Residues: A Platform for the Synthesis of Fidaxomicin Antibiotics
Angewandte Chemie International Edition·2024· 3 citedOpen Access
Switching Residues: Eine Plattform zur Synthese von Fidaxomicin Antibiotika
Angewandte Chemie·2024Open Access
Durlobactam to boost the clinical utility of standard of care β-lactams against <i>Mycobacterium abscessus</i> lung disease
Antimicrobial Agents and Chemotherapy·2024· 5 citedOpen Access
Correction: Synthesis and antibacterial action of 3’,6’-disubstituted spectinomycins
The Journal of Antibiotics·2024Open Access
18 Advancing combination treatments for Mycobacterium abscessus
Journal of Cystic Fibrosis·2024
Synthesis and antibacterial action of 3’,6’-disubstituted spectinomycins
The Journal of Antibiotics·2024· 3 citedOpen Access
Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in<i>Mycobacterium</i>abscessus
Proceedings of the National Academy of Sciences·2024· 12 citedOpen Access
Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species (ChemBioChem 24/2023)**
ChemBioChem·2023· 1 citedOpen Access
Dataset for "Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species"
Zenodo (CERN European Organization for Nuclear Research)·2023Open Access
page 1 of 15Next →

Frequent Co-authors

Erik C. Böttger(23), Burkhard Springer(15), Therdsak Prammananan(7), Peter M. Keller(6), Richard J. Wallace(5), A Meier(5), Vojo Deretić(4), M. Joseph Colston(4), Petra Selchow(4), Kadamba Papavinasasundaram(4), Sharon Master(3), Andreas Tschumi(3), Barbara A. Brown(3), Anna Rominski(3), Yishak G. Kidan(3), Kerstin Ellrott(3), Thomas Grau(3), Mandana Rezwan(3), Silvana K. Rampini(2), Christine Keller(2)